Skin Solutions

According to the 2026 clinical perspective, dark spot fading is no longer viewed as a simple bleaching process but as a gradual stabilization of inflammation and barrier function. OEM laboratory...

In 2026, uneven skin tone is increasingly viewed as a stability issue involving inflammation, barrier integrity, vascular responses, and epidermal turnover rather than excess pigment alone. Modern correction strategies focus...

In 2026, hyperpigmentation is increasingly viewed as a feedback loop involving inflammation, barrier dysfunction, and pigment signalling rather than simply excess melanin production. Modern treatment focuses on signal regulation and...

In 2026, tranexamic acid (TXA) is viewed less as a simple brightening ingredient and more as a regulator of the inflammation–pigment feedback loop. Clinical observations show that barrier damage, micro-inflammation,...

Hyperpigmentation in 2026 is increasingly viewed as an inflammatory memory issue rather than simple pigment accumulation. Clinical observations show that barrier instability, micro-inflammation, and over-treatment often drive rebound darkening and...

In 2026, BAO Laboratory distinguishes dark spots and melasma as biologically different conditions requiring separate formulation strategies. Dark spots mainly involve superficial inflammation and respond well to TXA, niacinamide, and...